ArticleCancer genomics & proteomics
Clinical Data Analysis Identifies Prognostic Long Non-coding RNA Signatures in Lung Adenocarcinoma.
Article in Cancer genomics & proteomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimLung adenocarcinoma (LUAD) is the most common subtype of non-small cell lung cancer (NSCLC) and remains associated with poor clinical outcomes due to pronounced molecular heterogeneity and limited prognostic biomarkers. Long non-coding RNAs (lncRNAs) have emerged as important regulators of cancer biology, yet their systematic association with disease progression and survival in LUAD remains incompletely defined. This study aimed to identify lncRNAs that robustly associate with LUAD progression and prognosis. MATERIALS AND
methodsPre-processed lncRNA expression data for 488 LUAD tumors and 58 normal lung tissues were obtained from The Cancer Genome Atlas (TCGA) via the TANRIC platform. Following expression filtering, stage-wise differential expression analysis was performed using Welch's t-test with false discovery rate correction. Kaplan-Meier survival analysis was used to evaluate prognostic relevance. Rank-based trend analyses using Spearman correlation were conducted to assess monotonic expression changes across tumor stage, lymph-node status, and tumor size.
resultsWe identified 68 lncRNAs consistently upregulated across all LUAD stages relative to normal lung tissue. Survival analysis revealed that higher expression of several lncRNAs was associated with poorer overall survival. Among these, FAM83A-AS1, CYTOR, and MIR4435-2HG emerged as prominent candidates, exhibiting consistent tumor-associated overexpression and adverse survival association. Importantly, these three lncRNAs also demonstrated significant monotonic trends across increasing lymph-node involvement and primary tumor size, indicating a close association with tumor burden and disease aggressiveness.
conclusionThis integrative analysis identifies FAM83A-AS1, CYTOR, and MIR4435-2HG as robust poor-prognosis-associated lncRNAs in LUAD. Their coordinated behavior across expression, survival, nodal status, and tumor size highlights their potential utility as prognostic biomarkers and provides a framework for lncRNA-based risk stratification in lung adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.